The adaptive, biomarker-directed trial allows researchers to enrich for best responders and open new sub-studies for non-responders based on emerging data.

Making clinical trials easier to find for clinicians and making protocols for entering clinical trials more lenient can help ...

While research in mice has shown encouraging results, the next phases of human trials will need to confirm safety and ...

Merck and Daiichi Sankyo have announced that the first patient has been dosed in the IDeate-Prostate01 phase 3 trial ...

Optical coherence tomography markers—like the ellipsoid zone—are reshaping clinical trials in intermediate age-related ...

OCCAM Immune, a Mount Sinai research organization, will sequence and map cells from samples collected in CRI's immunotherapy trials.

Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist ...

Xeris Biopharma Holdings is a company that has successfully launched products which are already generating revenue. Read why ...

In a new collaboration that could transform how cancer is treated, OCCAM Immune-a Mount Sinai initiative focused on ...

Specialist Consultant Paediatrician and Honorary Senior Fellow, Postgraduate Institute of Medicine, University of Colombo, ...

KANSAS CITY, Mo., June 17, 2025 /PRNewswire/ — NextStage Clinical Research is proud to announce the opening of its newest ...